In 2025, we made meaningful clinical progress, deepened scientific leadership through key publications, and expanded strategic collaborations. Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.

This holiday season, our team came together to support our communities in meaningful ways. Volunteering side by side not only allows us to give back - it strengthens our collaboration and sense of purpose long after the day of service ends.

Today, we announced promising interim results from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with mCRPC. CEO Markus Warmuth shares his perspective on the data. bit.ly/3KL2raf

We will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, December 16 to provide interim clinical results from the ongoing Phase 1/2 study of MRT-2359 in heavily pretreated metastatic castration-resistant prostate cancer patients. Access the webcast here: bit.ly/3KSVjbQ

Our colleagues break down the work behind this year’s Science Magazine cover story and what it means for the future of molecular glue degrader (MGD) development: bit.ly/3KvGUlL

Our invited review in @cp-trendsbiotech.bsky.social is now out in print. The piece explores how machine learning can predict de novo protein–protein interactions, including those induced by our molecular glues. Kudos to the team for their leadership in this rapidly expanding field: bit.ly/4plKI8g

Tune in for a fireside chat with Markus Warmuth at the Piper Sandler 37th Annual Healthcare Conference, where he’ll share insights on Monte Rosa and the progress of our molecular glue degraders. To register: bit.ly/44I2dam

Through proteomic profiling of our proprietary compound library, our team identified a selective, fast, and potent molecular glue degrader that induces cereblon degradation via a novel mechanism. Read the full paper in @natcomms.nature.com: rdcu.be/eQKQk

ICYMI, this year we were thrilled to be named “Biotech of the Year” at the 8th Annual #TPD and Induced Proximity Summit. Thanks to the organizers for setting up a great meeting, and congratulations to our entire team.

In London for the Jefferies Global Healthcare Conference, or following along virtually? Join our CEO, Markus Warmuth, for a fireside chat as he reviews the latest on our pipeline programs. Register or view the webcast: bit.ly/3X0oso4

Our CMO, Filip Janku, will participate in a virtual fireside chat at the TD Cowen Immunology & Inflammation Summit to discuss how we're advancing our I&I portfolio. Register or view the webcast: bit.ly/4p8Inx1

ICYMI: We presented preclinical data at #AHA2025 showing that degrading NEK7 to modulate the NLRP3 inflammasome offers a novel, differentiated approach with potential in cardiovascular and cardiometabolic diseases. Learn more: bit.ly/3XjONNQ

CEO Markus Warmuth shares his perspective on the future of Monte Rosa and molecular glue degraders in a fireside chat today at the Guggenheim 2nd Annual Healthcare Innovation Conference. To register: bit.ly/4qIpZwq

Today, we present preclinical data on the potential of MRT-8102, a first-in-class, NEK7-directed MGD for inflammatory diseases driven by the NLRP3 inflammasome at AHA Scientific Sessions 2025. Learn more: bit.ly/43SJQiF #AHA2025

Today, we report financial results and business highlights for the third quarter 2025. Read more: bit.ly/43f5vBo

ICYMI: our team presented data at #ACR25 showing MRT-6160, a first-in-class VAV1-directed MGD, inhibited disease pathology in a preclinical autoimmune model. CSO Sharon Townson shares perspective on the significance of these findings. View the poster: bit.ly/3L955q7

At #ACR25? Join Marisa Peluso as she presents the latest preclinical data on the potential of MRT-6160, a VAV1-directed molecular glue degrader, to treat immune-mediated diseases. Read the full press release here: bit.ly/4o7koyf

Proud to be recognized among the “Six Targeted Protein Degrader Companies to Watch” by @clarivatelsh.bsky.social. Learn more about our pioneering work in molecular glue degraders and download the full report here: bit.ly/4odvdye

Adam Cartwright presents preclinical data today at #ECTRIMS2025 suggesting MRT-6160, a first-in-class VAV1-directed MGD, has the potential to benefit patients with neuroinflammatory diseases as well as other T- and B-cell immune-mediated conditions: bit.ly/3KEi7vf

David Wild of In Vivo had an insightful conversation with our CEO, Markus Warmuth, and CDIO, John Castle, about the past, present, and future of Monte Rosa, and the broad, growing potential of molecular glues. Read more [note that content is paywalled]: bit.ly/4gEiIJB

This week’s announcement of a second collaboration with @novartis.bsky.social includes an exclusive license to an undisclosed discovery target and options to license two preclinical immunology programs. CEO Markus Warmuth comments: bit.ly/3Vl0yTg

Today we announced our second collaboration with @novartis.bsky.social to develop novel degraders for immune-mediated diseases. Given the strong progress we’ve made on our collaboration advancing VAV1 degraders, we’re thrilled to be collaborating with them again: bit.ly/3Vl0yTg

At this year’s 2025 Stifel I&I Forum, our CEO, Markus Warmuth, will participate in a fireside chat and provide an overview of our I&I pipeline progress. Learn more: bit.ly/41PXdiR

As part of this year’s Dana-Farber TPD Webinar series, Georg Petzold will present on how we’ve upended the paradigm of what is possible with cereblon-based molecular glue degraders. We hope you can join! www.danafarbertargetedproteindegradation.org

John Castle sat down with Jim Cornall of LabiotechEU to discuss how our team and AI-driven QuEEN™ discovery engine are redefining what’s possible with molecular glues. The episode aired on Freddie Mercury’s birthday. Give it a listen, it will “Rock You”! bit.ly/3IbPNQ7

Learn more about the people, passion and precision shaping the future of targeted protein degradation: bit.ly/4mhJDNf

August is Autoinflammatory Awareness Month – a time to elevate understanding of immune-driven conditions. At Monte Rosa, we’re advancing science in immunology and inflammation to help bring forward new options for patients: bit.ly/4fyevqj @autoinflammatory.bsky.social

Today, we report financial results and business highlights for the second quarter 2025. Read more: bit.ly/45pOnJC

Thanks to Alex Eccleston of Nature Reviews Drug Discovery for a very nice summary of our recent Science Magazine publication. If you don’t have time to read the full paper, make the time! Or read this summary, which provides a great overview. www.nature.com/articles/d41...

A big thank you to our fantastic 2025 interns, who include Lauren Brooks, Ramya Naraharisetti, Amit Pandey, Enea Pinchetti, and Mathilde Hemery! We’re grateful for their excellent work and the insights they share here on their experiences at Monte Rosa. #NationalInternDay

We’re excited to announce the first subjects have been dosed in a Phase 1 study of MRT-8102, a NEK7-directed MGD being developed for inflammatory conditions linked to the NLRP3 inflammasome, IL-1β, and IL-6. Learn more: bit.ly/4m5JOe7

Exceptional individuals united as a team are critical to our success. Join us on our epic journey from one of two base camps – Boston and Basel. To view open positions, visit: bit.ly/44yYQmP

Grateful to Sally Church for her incisive review of our recent @science.org manuscript, capturing its significance — from target space expansion to pharmacologic implications to the evolving therapeutic landscape. @maverickny.bsky.social biotechstrategyblog.com/2025/07/how-...

Sharon Townson and John Castle comment on our groundbreaking work recently featured on the cover of Science Magazine, @science.org. We’ve shown the molecular glue target space is broader than previously understood, and we believe we are uniquely positioned to harness its potential: bit.ly/4koxZ1m

ICYMI: Last week, we published discoveries in a Science Magazine (@science.org) cover story that enable the next generation of molecular glue degrader (MGD) medicines and vastly expand the number of potential targets addressable with MGDs and our QuEEN™ discovery engine. bit.ly/4kvoGwH

Today, we're presenting new data on MRT-6160 – a first-in-class, rationally designed MGD that selectively targets VAV1 – supporting its potential to benefit patients with neuroinflammatory diseases and other immune-mediated conditions. bit.ly/442bWZv #FOCIS2025

Our AI-powered QuEEN discovery engine has delivered a pipeline of novel molecular glue degraders that selectively degrade high-potential, hard-to-drug proteins, offering new treatment possibilities in key therapeutic areas. Explore our pipeline: bit.ly/4jWZpuN

Monte Rosa presents new preclinical data on our NEK7-directed molecular glue degrader, MRT-8102, this week at #EULAR2025. These findings highlight the potential of NEK7-targeting MGDs as a promising therapeutic approach for multiple inflammatory diseases.

Pleased to announce FDA clearance of our IND application for MRT-8102, a NEK7-directed molecular glue degrader designed to target inflammatory diseases driven by the NLRP3 inflammasome, IL-1β, and IL-6. Learn more: bit.ly/3FS1Roz

Please join us as our CEO Markus Warmuth participates in a fireside chat today at the Jefferies Global Healthcare Conference in New York, sharing insight into our recent progress and strategic priorities: bit.ly/4jDbrtt #JefferiesHealthcare

At Monte Rosa, we're advancing high-throughput proteomics to accelerate target ID for molecular glue degraders – and sharing our latest at #ASMS2025. Join us to learn more about how our proprietary platform is driving speed, depth & reproducibility in MGD drug discovery.

Proud to share our invited review in @cp-trendsbiotech.bsky.social on using machine learning to predict de novo protein-protein interactions – pushing beyond nature’s blueprint to enable new advances in drug discovery and protein engineering. Congrats to the team: bit.ly/3Zy4thY

What if we could map the surface features that make a protein degradable? At Monte Rosa, we’re doing just that – creating ‘glueprints’ to rationally design molecular glue degraders for previously undruggable targets. Our latest preprint explains how: bit.ly/4d3vxex

At #AACR25? Join Nina Ilic-Widlund and Sofia Gkountela as they present the latest preclinical data on Monte Rosa’s novel molecular glue degrader for the potential treatment of HR-positive/HER2-negative breast cancer. Read the full press release here: bit.ly/3GFQDU4

This week at #AACR25, we will present preclinical data on our highly selective cyclin-dependent kinase 2 (CDK2)-directed molecular glue degrader in HR-positive/HER2-negative breast cancer. CSO Sharon Townson comments on our innovative approach: bit.ly/3GFQDU4

Using geometric deep learning to identify targets, protein surfaces to match targets to ligases, and virtual screening to design MGDs, our integrated data moat and AI algorithms guide our drug discovery. Learn more: bit.ly/3PMIYEQ

Monte Rosa’s proprietary QuEEN discovery engine works at the interface of technology and life sciences to rewrite drug discovery. Using QuEEN, we've made highly selective, long duration, catalytic molecular glue degraders that deeply modulate disease pathways. Discover how: bit.ly/3PMIYEQ

We’re making meaningful strides in I&I - advancing key programs and leveraging our proprietary QuEEN™ discovery engine to build a highly differentiated portfolio of oral I&I therapies. Hear more in our latest pipeline update and earnings webcast: bit.ly/42p9YjV

Cyclin E1 and CDK2 are well-validated targets for treating certain cancers, however, there are limits with conventional approaches. Our highly selective molecular glue degraders are designed to address these challenges. CSO Sharon Townson shares more: bit.ly/42p9YjV

Our rationally designed molecular glue degraders demonstrate exquisite selectivity & have the potential to transform treatment approaches in immunology & inflammation. Hear more from CSO Sharon Townson and our executive team: bit.ly/42p9YjV